Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5–11 Years — United States, October 12–January 1, 2023
Anne M. Hause, Paige Marquez, Bicheng Zhang, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 2, pp. 39-43
Open Access | Times Cited: 23

Showing 23 citing articles:

Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysis
Vanessa Piechotta, Waldemar Siemens, Iris Thielemann, et al.
The Lancet Child & Adolescent Health (2023) Vol. 7, Iss. 6, pp. 379-391
Open Access | Times Cited: 51
COVID-19 annual update: a narrative review
Michela Biancolella, Vito Luigi Colona, Lucio Luzzatto, et al.
Human Genomics (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 28
Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England
Emma Copland, Martina Patone, Defne Saatci, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Overview of U.S. COVID-19 vaccine safety surveillance systems
Julianne Gee, Tom T. Shimabukuro, John R. Su, et al.
Vaccine (2024) Vol. 42, pp. 125748-125748
Open Access | Times Cited: 7
A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children
Frances Priddy, Spyros Chalkias, Brandon Essink, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 862-878
Open Access | Times Cited: 4
The COVID-19 pandemic in children and young people during 2022–24: what new did we learn?
Igor Rudan, Steven Kerr, Colin R Simpson, et al.
Journal of Global Health (2025) Vol. 15
Open Access
New variants of COVID‐19 (XBB.1.5 and XBB.1.16, the “Arcturus”): A review of highly questioned concerns, a brief comparison between different peaks in the COVID‐19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at‐risk groups
Homa Pourriyahi, Nima Hajizadeh, Mina Khosravi, et al.
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 6
Open Access | Times Cited: 3
Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern
Monika Kumari, Shih-Chieh Su, Kang-Hao Liang, et al.
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 8
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
Chayanit Mahasing, Pawinee Doung‐ngern, Rittichai Jaipong, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 749-749
Open Access | Times Cited: 7
Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
Donald J. Alcendor, Patricia Matthews-Juarez, Duane T. Smoot, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 906-906
Open Access | Times Cited: 7
Safety Monitoring of mRNA COVID-19 Vaccine Third Doses Among Children Aged 6 Months–5 Years — United States, June 17, 2022–May 7, 2023
Anne M. Hause, Paige Marquez, Bicheng Zhang, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 23, pp. 621-626
Open Access | Times Cited: 7
The Effectiveness of Bivalent COVID-19 Vaccination: A Preliminary Report
Ssu-Yu Chen, Chien‐Yu Lin, Hsin Chi, et al.
Life (2023) Vol. 13, Iss. 10, pp. 2094-2094
Open Access | Times Cited: 7
Booster vaccination using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5–11 years: a phase 2/3, randomized, active-controlled study
Rino Suzuki, Miharu Suda, Katsuyasu Ishida, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Live‐virus neutralization of the omicron variant in children and adults 14 months after SARS‐CoV‐2 wild‐type infection
Maximilian Stich, Louise Benning, Claudius Speer, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 3
Open Access | Times Cited: 4
Dilemmas and options for COVID-19 vaccination in children
Jingzhi Wen, Xiaoan Du, A. Li, et al.
˜The œItalian Journal of Pediatrics/Italian journal of pediatrics (2023) Vol. 49, Iss. 1
Open Access | Times Cited: 4
Global COVID-19 vaccination in infants and children: Effectiveness, safety, and challenges
Watsamon Jantarabenjakul, Napaporn Chantasrisawad, Rapisa Nantanee, et al.
Asian Pacific Journal of Allergy and Immunology (2023)
Open Access | Times Cited: 3
COVID-19 Vaccines in Children
Danielle Fayad, Robert W. Frenck
Journal of Clinical Medicine (2023) Vol. 13, Iss. 1, pp. 87-87
Open Access | Times Cited: 2
Safety and antibody response of the BNT162b2 SARS-CoV-2 vaccine in children aged 5–11 years with underlying diseases: A prospective observational study
Takanori Funaki, Masaki Yamada, Kozue Miyake, et al.
Journal of Infection and Chemotherapy (2024) Vol. 30, Iss. 8, pp. 773-779
Closed Access
Revaccination against COVID-19: Current Status of the Problem
N. P. Andreeva, S. R. Racic, S. V. Lezhenina, et al.
Epidemiology and Vaccinal Prevention (2024) Vol. 23, Iss. 2, pp. 94-101
Open Access
A descriptive review on the real-world impact of Moderna, inc. COVID-19 vaccines
Mary T. Bausch-Jurken, Rachel Dawson, Francesca Ceddia, et al.
Expert Review of Vaccines (2024)
Open Access
Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds
Lawrence Sher, Justice K. Boakye-Appiah, Sungeen Hill, et al.
Journal of the Pediatric Infectious Diseases Society (2024) Vol. 13, Iss. 8, pp. 421-429
Open Access
Humoral Response after a Fourth Dose with mRNA-1273 in Healthcare Workers with and without a History of SARS-CoV-2 Infection and Previously Vaccinated with Two Doses of BBIBP-CorV Plus BNT162b2 Vaccine
Juan Carlos Gómez de la Torre, Miguel Hueda-Zavaleta, José Alonso Cáceres-DelAguila, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 894-894
Open Access | Times Cited: 1
Immunogenicity of coronavirus disease 2019 vaccines in children: A review with ChatGPT
Daniel Leung, Jaime S. Rosa Duque, Wenwei Tu, et al.
Pediatric Discovery (2023) Vol. 1, Iss. 1
Open Access | Times Cited: 1
Coronavirus disease 2019 vaccine in pediatric post‐kidney transplantation
Aziza Ajlan, Hassan Aleid, Tariq Ali, et al.
Clinical Transplantation (2023) Vol. 37, Iss. 6
Closed Access
Page 1

Scroll to top